Analysts Anticipate Humana Inc (HUM) to Announce $2.58 Earnings Per Share

Wall Street brokerages predict that Humana Inc (NYSE:HUM) will report $2.58 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Humana’s earnings, with the lowest EPS estimate coming in at $2.43 and the highest estimate coming in at $2.84. Humana reported earnings per share of $2.06 in the same quarter last year, which would suggest a positive year over year growth rate of 25.2%. The business is scheduled to report its next quarterly earnings results on Wednesday, February 6th.

On average, analysts expect that Humana will report full year earnings of $14.25 per share for the current year, with EPS estimates ranging from $14.14 to $14.46. For the next year, analysts forecast that the firm will post earnings of $17.36 per share, with EPS estimates ranging from $16.92 to $18.09. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Humana.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 EPS for the quarter, beating the Zacks’ consensus estimate of $4.29 by $0.29. Humana had a return on equity of 17.43% and a net margin of 2.48%. The company had revenue of $14.21 billion during the quarter, compared to the consensus estimate of $13.97 billion. During the same period in the previous year, the firm posted $3.39 earnings per share.

HUM has been the subject of several analyst reports. Morgan Stanley initiated coverage on Humana in a research report on Thursday, July 12th. They set an “overweight” rating and a $362.00 price objective for the company. Royal Bank of Canada reiterated a “hold” rating and set a $318.00 price objective on shares of Humana in a research report on Thursday, August 2nd. Jefferies Financial Group boosted their price objective on Humana from $356.00 to $372.00 and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Bank of America boosted their price objective on Humana from $338.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $355.00 price objective on shares of Humana in a research report on Thursday, August 2nd. Seven analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $352.30.

Shares of HUM stock opened at $339.59 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43. Humana has a 52 week low of $231.90 and a 52 week high of $355.88. The company has a market capitalization of $45.71 billion, a price-to-earnings ratio of 29.00, a P/E/G ratio of 1.65 and a beta of 1.03.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, December 28th. This represents a $2.00 annualized dividend and a yield of 0.59%. Humana’s payout ratio is 17.08%.

In related news, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the business’s stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $330.00, for a total value of $1,020,360.00. Following the sale, the insider now directly owns 14,289 shares in the company, valued at approximately $4,715,370. The disclosure for this sale can be found here. 0.60% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in the stock. Raymond James Trust N.A. increased its holdings in shares of Humana by 19.8% in the second quarter. Raymond James Trust N.A. now owns 956 shares of the insurance provider’s stock valued at $284,000 after buying an additional 158 shares in the last quarter. Financial Gravity Wealth Inc. increased its holdings in shares of Humana by 41.9% in the third quarter. Financial Gravity Wealth Inc. now owns 562 shares of the insurance provider’s stock valued at $179,000 after buying an additional 166 shares in the last quarter. Daiwa SB Investments Ltd. increased its holdings in shares of Humana by 27.9% in the second quarter. Daiwa SB Investments Ltd. now owns 780 shares of the insurance provider’s stock valued at $232,000 after buying an additional 170 shares in the last quarter. Advisor Partners LLC increased its holdings in shares of Humana by 5.3% in the second quarter. Advisor Partners LLC now owns 3,604 shares of the insurance provider’s stock valued at $1,073,000 after buying an additional 180 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its holdings in shares of Humana by 1.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 11,901 shares of the insurance provider’s stock valued at $3,541,000 after buying an additional 197 shares in the last quarter. 92.62% of the stock is currently owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Further Reading: Google Finance

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply